Kala Bio, Inc. (KALA): Total Assets
$9.49M
As of 2025-12-31
$10.58M
As of 2026-06-30
-52.2%
3-year compound annual growth
-46.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.49M | -82.9% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $55.48M | -0.8% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $55.95M | -35.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $86.82M | -37.7% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $139.43M | -37.1% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $221.61M | +43.6% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $154.32M | -30.2% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $220.97M | +89.6% | 2020-02-12, Balance as of period end |
| 2017-12-31 | $116.55M | +151.6% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $46.33M | n/a | 2018-04-02, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Kala Bio, Inc. (KALA) | 2025-12-31 | $9.49M | -82.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare KALA, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗